With over two decades devoted to practicing patent law, Olga Berson offers an unparalleled blend of legal skill and technical acumen. Olga handles complex issues in diverse technical areas including biopharmaceuticals (small and large molecules), drug delivery platforms, medical devices, analytical methods and equipment, skincare and cosmetics, foods and nutraceuticals, and commodity and specialty chemicals and materials. Olga’s strong technical foundation and academic training—including a Ph.D. in environmental science and chemistry from Caltech—allow her to work effectively with inventors and scientific experts and to distill complex technical matters into compelling legal arguments that resonate in both boardrooms and courtrooms.
With a focus on intellectual property (IP) due diligence, Olga conducts patent portfolio and patent landscape analyses, evaluates IP licensing and technology agreements, and assesses the financial and operational risks associated with patent disputes and potential litigation. Her advice is frequently sought for due diligence investigations related to mergers, acquisitions, collaborations, divestitures, recapitalizations, and bankruptcies. She serves a diverse client base, from multinational corporations to emerging startups and venture capital firms.
Olga also undertakes patent audits and internal evaluations, helping clients identify either licensing opportunities or strategic patent abandonments. She guides clients in preparing for product launches and provides valuable counsel on freedom-to-operate strategies and patent validity. She understands the intricate relationship between US Food and Drug Administration (FDA) regulations and patent issues. Olga’s considerable litigation background, including Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA) matters, not only enhances her IP due diligence practice but also enables her to proactively mitigate potential litigation risks for clients.
Olga’s recent work involved the commercialization of a COVID-19 vaccine, the acquisition of an immunology company, and the evaluation of patent portfolios in areas including immunology, oncology, and neurodegenerative diseases. She has also conducted patent landscape analyses to facilitate the launches of biosimilar versions of blockbuster monoclonal antibodies.
Beyond her IP due diligence practice, Olga assists clients with strategic patent portfolio development. She also handles Hatch-Waxman, BPCIA, and biologics patent litigation, as well as US Patent and Trademark Office proceedings. With her wide-ranging technical and legal capabilities, Olga serves as an invaluable asset for clients requiring comprehensive and insightful IP solutions.
Patent Due Diligence Investigations
Strategic Patent Portfolio Development and Counseling
Patent Litigation and Post-Grant Proceedings
Life Sciences Star, Patent Strategy & Management, LMG Life Sciences (2024)
Life Sciences Star, Intellectual Property, LMG Life Sciences (2022)
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)
Member, American Bar Association
Member, American Chemical Society
Rising Star, Intellectual Property, Super Lawyers (2005, 2008)
Rising Star, Intellectual Property Litigation, Super Lawyers (2005, 2008)